Applications of Recombinant Protein Production

Published: 9월 8, 2026

Recombinant proteins play a pivotal role in the prevention, diagnosis, and treatment of numerous diseases, making them one of the fastest-growing segments of the pharmaceutical industry. Additionally, recombinant proteins are widely used in research and biotechnology for studying protein function, drug discovery, assay development, structural biology, and synthetic biology applications.16

Key Takeaways

  • Recombinant proteins are used across therapeutic, biopharmaceutical, diagnostic, research, and biotechnology applications.
  • Applications include monoclonal antibodies, hormone replacement therapies, enzyme replacement therapies, vaccines, and blood coagulation factors.
  • Recombinant proteins also support functional studies, biomarker research, assay development, and diagnostics.
  • Protein production challenges can be addressed through careful process optimization, analytical methods, and laboratory automation. 

Therapeutic and Biopharmaceutical Applications 

Application Area Example
Monoclonal Antibodies Trastuzumab (Herceptin®) is a recombinant monoclonal antibody targeting HER2 and is used to treat HER2-positive breast cancer and gastric cancer.26
Hormone Replacement Therapy Recombinant erythropoietin (epoetin alfa) is widely used to manage anemia associated with chronic kidney disease.7
Enzyme Replacement Therapy Imiglucerase, a recombinant form of glucocerebrosidase, is used as enzyme replacement therapy for Gaucher disease, a lysosomal storage disorder.20
Vaccines Recombinant Hepatitis B vaccines (e.g., Engerix-B®, Recombivax HB®) contain recombinant hepatitis B surface antigen (HBsAg) and are used to prevent hepatitis B virus infection.17
Blood Coagulation Factors Recombinant Factor VIII is used for the treatment and prevention of bleeding episodes in patients with Hemophilia A.27
Cytokines and Growth Factors Interferon-α has been used in the treatment of chronic viral hepatitis..28
Targeted Therapies Personalized therapeutic cancer vaccines predicated on neoantigens have been shown to be feasible, safe and immunogenic in patients with melanoma and glioblastoma3

Table 2. Representative therapeutic, diagnostic, and research applications of recombinant proteins, with examples used in biopharmaceutical development, vaccines, biomarker discovery, and biotechnology.

 

Applications in Research and Biotechnology

Functional Studies of Proteins

Example: Green Fluorescent Protein (GFP) is a recombinant protein widely used as a reporter molecule to study gene expression regulation, organelle labeling, signal transmission, drug screening, and biomolecular interactions in living cells.6

Biomarker Discovery and Validation

Example: Recombinant SARS-CoV-2 Spike (S) protein has been extensively used as a biomarker antigen.5

Assay Development and Diagnostics

Example: Recombinant SARS-CoV-2 Spike protein and GFP-tagged recombinant proteins are used to develop ELISA-based diagnostic assays.5

View References
  1. Alhammad LA, Ainosah TK, Ahmad AM et al. (2023). The impact of laboratory automation on efficiency and accuracy in healthcare settings. International Journal Of Community Medicine And Public Health, 11(1), 459–463.
  2. Bhatwa A, Wang W, Hassan YI et al. (2021). Challenges Associated With the Formation of Recombinant Protein Inclusion Bodies in Escherichia coli and Strategies to Address Them for Industrial Applications. Frontiers in Bioengineering and Biotechnology. 9:630551.
  3. Blass E, Ott PA. (2021). Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nature Reviews Clinical Oncology. 18, 215–229.
  4. Cha H, Park J-H. (2021). Recombinant Human Erythropoietin Production in Chinese Hamster Ovary Cells Is Enhanced by Supplementation of α-Helix Domain of 30Kc19 Protein. Applied Sciences. 11(22):11009.
  5. Chabot et al. (2026). Development of a recombinant membrane protein ELISA for analyzing antibody responses against SARS-CoV-2 envelope proteins. Journal of Biological Chemistry. Volume 302(1).
  6. Chen Y-L, Xie X-X, Zhong N et al. (2023). Research Progresses and Applications of Fluorescent Protein Antibodies: A Review Focusing on Nanobodies. International Journal of Molecular Sciences. 24(5):4307.
  7. Creangă EC, Stan R, Nicolae AC et al. (2025). Personalized Therapeutic Advances in Erythropoietin Signaling: From Anemia Management to Extensive Clinical Applications. Pharmaceutics. 17(9):1190.
  8. Echelard Y, Meade HM, Ziomek CA. (2006). Production of Recombinant Therapeutic Proteins in the Milk of Transgenic Animals. BioPharm International. 19(8).
  9. Gupta V, Sengupta M, Prakash J et al. (2017). Production of Recombinant Pharmaceutical Proteins. In: Basic and Applied Aspects of Biotechnology. Springer, Singapore.
  10. Gupta V et al. (2016). Production of Recombinant Pharmaceutical Proteins. Basic and Applied Aspects of Biotechnology. 77–101.
  11. Hernandez SI, Berezin CT, Miller KM et al. (2024). Sequencing Strategy to Ensure Accurate Plasmid Assembly. ACS Synthetic Biology. 13(12):4099-4109.
  12. Hong M, Li T, Xue W et al. (2022). Genetic engineering of baculovirus-insect cell system to improve protein production. Frontiers in Bioengineering and Biotechnology. 10:994743.
  13. Hou L, Zhang XY, Li Y et al. (2016). Rapid Screening of Recombinant Plasmids by Direct Colony Quantitative Real-Time PCR. Advances in Bioscience and Biotechnology. 7, 428-433.
  14. Beckman Coulter. Nanoliter-Scale DNA Assembly with the Echo 525 Liquid Handler Application Note.
  15. Jayakrishnan A, Wan Rosli WR, Tahir ARM et al. (2024). Evolving Paradigms of Recombinant Protein Production in Pharmaceutical Industry: A Rigorous Review. Sci. 6(1):9.
  16. Kumar V, Barwal A, Sharma N et al. (2024). Therapeutic proteins: developments, progress, challenges, and future perspectives. 3 Biotech. 14, 112.
  17. Mahmood F, Xu R, Awan MUN et al. (2023). HBV Vaccines: Advances and Development. Vaccines. 11(12):1862.
  18. Martins JT, Bourbon AI, Pinheiro AC et al. (2018). Protein-Based Structures for Food Applications: From Macro to Nanoscale. Frontiers in Sustainable Food Systems. 2:77.
  19. Ojima-Kato T. (2025). Advances in recombinant protein production in microorganisms and functional peptide tags. Bioscience, Biotechnology, and Biochemistry. 89(1).
  20. Pastores GM. (2010). Recombinant Glucocerebrosidase (Imiglucerase) as a Therapy for Gaucher Disease. BioDrugs. 24, 41–47.
  21. Rosano GL, Morales ES, Ceccarelli EA. (2019). New tools for recombinant protein production in Escherichia coli: A 5-year update. Protein Science. 28(8):1412-1422.
  22. Shanmugaraj B, Bulaon CJI, Phoolcharoen W. (2020). Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production. Plants. 9(7):842.
  23. Shilling PJ, Mirzadeh K, Cumming AJ et al. (2020). Improved designs for pET expression plasmids increase protein production yield in Escherichia coli. Communications Biology. 3, 214.
  24. Wang W. (2015). Advanced protein formulations. Protein Science. 24(7):1031-9.
  25. Wu et al. (2025). Automating an Adeno-associated Virus (AAV) Functional Assay Using the Biomek i7 Liquid Handler with Integrated Vi-CELL BLU Analyzer. Application Note.
  26. Swain SM, Shastry M, Hamilton E. (2023). Targeting HER2-positive breast cancer: advances and future directions. Nature Reviews Drug Discovery. 22(2):101-126.
  27. Konkle B, Oldenburg J, Pasi J et al. (2023). Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults.
  28. Gao Y, Yin Y, Xie P et al. (2025). Interferon in Liver Diseases: Recent Advances. Advances in Therapy. 42, 4210–4223.

Explore Related Protein Production Topics

Continue exploring the technologies, workflows, and applications that support efficient and scalable recombinant protein production.

FAQ on Applications of Recombinant Protein Production

What factors most impact protein yield during expression and purification?

Protein yield is influenced by the expression host, gene and vector design, culture conditions, and the host cell's ability to properly modify the protein. Yield can be reduced by protein aggregation, inclusion body formation, proteolytic degradation, and poor solubility, while buffer composition, pH, purification strategy, and protein stability directly impact recovery and product quality during purification.2,15

Basse Hofzumahaus 

Basse Hofzumahaus 

Product Marketing Manager 

About the author:

Basse Hofzumahaus brings 15+ years of experience in life sciences, across academia, R&D, and product management. With a PhD and M.Sc. in Biotechnology, he connects scientific depth with a focus on upstream bioprocessing, microbial fermentation, CHO workflows, clone screening, and microbioreactor development. 

Talk to an Expert